Related Experiment Video

Updated: Jun 22, 2026

Large Animal Model for Evaluating the Efficacy of the Gene Therapy in Ischemic Heart
06:07

Large Animal Model for Evaluating the Efficacy of the Gene Therapy in Ischemic Heart

Published on: September 2, 2021

Ischemic heart diseases: current treatments and future

Donghoon Choi1, Ki-Chul Hwang, Kuen-Yong Lee

  • 1Division of Cardiology, Yonsei Cardiovascular Hospital, Yonsei Cardiovascular Research Institute, Yonsei University, College of Medicine, Seoul, 120-749, Republic of Korea.

Journal of Controlled Release : Official Journal of the Controlled Release Society
|July 1, 2009
PubMed

Insights

Ischemic heart disease treatment is evolving from conventional therapies to promising biopharmaceutical approaches like protein, gene, and cell therapy for improved cardiac blood flow.

Area of Science:

  • Cardiovascular Medicine
  • Biotechnology
  • Regenerative Medicine

Background:

  • Ischemic heart disease (IHD) is a leading global cause of mortality, characterized by insufficient oxygen supply to cardiac muscles due to coronary artery stenosis.
  • Conventional treatments for IHD include drug-eluting stents, bypass surgery, and anti-thrombotic medications.
  • Biopharmaceutical therapies offer novel strategies for IHD management.

Purpose of the Study:

  • To review the current landscape of ischemic heart disease treatments.
  • To explore the potential of biopharmaceutical-based therapies, including protein, gene, and cell therapy.
  • To discuss the role of polymeric hydrogels in delivering therapeutic proteins for IHD.

Main Methods:

  • Literature review of conventional and biopharmaceutical treatments for ischemic heart disease.
  • Analysis of protein, gene, and cell-based therapeutic strategies.
  • Examination of polymeric hydrogels as delivery systems for therapeutic proteins.

Main Results:

  • Biopharmaceutical therapies show promise in promoting neovascularization and enhancing collateral blood flow in ischemic hearts.
  • Protein, gene, and cell transplantation are recognized as key biopharmaceutical approaches.
  • Polymeric hydrogels are being investigated for efficient delivery of therapeutic proteins.

Conclusions:

  • Biopharmaceutical therapies represent a significant advancement in treating ischemic heart disease.
  • Future directions include optimizing protein delivery systems like polymeric hydrogels for enhanced therapeutic efficacy.
  • Further research is needed to fully realize the potential of these novel treatments for IHD.

More Related Videos

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

Related Concept Videos

Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...